

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 2

Complete if Known

Application Number	10/594,473
Filing Date	11-13-2007
First Named Inventor	Xian-Ming Zeng
Art Unit	1615
Examiner Name	Randeep Singh
Attorney Docket No.	TEVE-124US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)				
/R.S./		WO-2004/017918-A2	03-04-2004	Ivax Corporation; Norton Healthcare Ltd.		<input type="checkbox"/>
/R.S./		WO-95/00128-A1	01-05-1995	Astra Aktiebolag		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner
Signature

/Randeep Singh/

Date
Considered

05/05/2012

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 2 of 2

Complete if Known

Application Number	10/594,473
Filing Date	11-13-2007
First Named Inventor	Xian-Ming Zeng
Art Unit	1815
Examiner Name	Randeep Singh
Attorney Docket No.	TEVE-124US

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/R.S./		BEGAT et al., "The Role of Force Control Agents in High-Dose Dry Powder Inhaler Formulations," <i>Journal of Pharmaceutical Sciences</i> , Vol. 98, No. 8, August 2009, pp. 2770-2783.	<input type="checkbox"/>
/R.S./		IKEGAMI et al., "Simultaneous particulate design of primary agglomerated crystals of steroid by spherical agglomeration in liquid for dry powder inhalation," <i>Powder Technology</i> , 2003, Vol. 130, pp. 290-297.	<input type="checkbox"/>
/R.S./		IKEGAMI et al., "In vitro inhalation behavior of spherically agglomerated steroid particles with carrier lactose," <i>Advanced Powder Technol.</i> , 2000, Vol. 11, No. 3, pp. 323-332.	<input type="checkbox"/>
/R.S./		DE VILLIERS, "Description of the kinetics of the deagglomeration of drug particle agglomerates during powder mixing," <i>International Journal of Pharmaceutics</i> , 1997, Vol. 151, pp. 1-6.	<input type="checkbox"/>
/R.S./		RODRIGUEZ-VÁZQUEZ et al., "Assessment of the bronchodilator effect of inhaled furosemide compared to salbutamol in asthmatic patients," <i>Invest. Allergol. Clin. Immunol.</i> , March-April 1998, Vol. 8, No. 2, pp. 115-118.	<input type="checkbox"/>
/R.S./		DE VILLIERS et al., "Dissolution Rate a Measurement of the Deaggregation of Furosemide Agglomerates During an Interactive Mixing Process," <i>Drug Development and Industrial Pharmacy</i> , 1990, Vol. 6, No. 8, pp. 1391-1397.	<input type="checkbox"/>
/R.S./		CARTILIER et al., "Effect of Flowing Adjuvants on the Homogeneity and the Kinetics of Mixing of Low Dosage Cohesive Powder Mixtures," <i>Drug Development and Industrial Pharmacy</i> , 1986, Vol. 12, Nos. 8 & 9, pp. 1203-1218.	<input type="checkbox"/>
/R.S./		Opposition Statement dated 18 November 2011 (Opposition by AstraZeneca AB to European Patent No. 1 699 434).	<input type="checkbox"/>
/R.S./		Statement of Facts & Arguments dated 16 November 2011 (Opposition by Vectura Limited to European Patent No. 1 699 434).	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner
Signature

/Randeep Singh/

Date
Considered

05/05/2012

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional).²Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.